Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759987 | 0.88 | MEN1 (0.68) | MEN1GAAKMT2ASLC1A1SLC1A3 | |
| SCHEMBL3916161 | 0.86 | MEN1 (0.63) | MEN1GAAKMT2ASLC1A1SLC1A3 | |
| SCHEMBL18394313 | 0.86 | MEN1 (0.63) | MEN1GAAKMT2ASLC1A1SLC1A3 | |
| SCHEMBL352610 | 0.86 | MEN1 (0.63) | MEN1GAAKMT2ASLC1A1SLC1A3 | |
| SCHEMBL18992249 | 0.85 | MEN1 (0.67) | MEN1GAAKMT2ASLC1A1SLC1A3 | |
| Hydrochloric Acid SCHEMBL4433195 | 0.84 | MEN1 (0.61) | MEN1GAAKMT2ASLC1A1SLC1A3 | |
| SCHEMBL15376152 | 0.81 | MEN1 (0.71) | MEN1GAAKMT2A | |
| SCHEMBL12341083 | 0.81 | MEN1 (0.71) | MEN1GAAKMT2A | |
| SCHEMBL28079376 | 0.81 | MEN1 (0.71) | MEN1GAAKMT2A | |
| SCHEMBL27594927 | 0.81 | MEN1 (0.71) | MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021050-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-7211580-B2 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED (US) | 2007-05-01 | — | — | US | disclosed |
| US-20040142949-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021050-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | MEN1 1449/4885GAA 314/4885KMT2A 1458/4885 |
| US-20040142949-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | MEN1 1449/4885GAA 314/4885KMT2A 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.